Drug patent plan gets mixed reviews
Monday, February 23, 2009 - 20:21
in Health & Medicine
GlaxoSmithKline's bid to tackle neglected diseases receives a muted response from the rest of the industry.
Updated by artificial intelligence Tue, 13 Jun 2023, 2:53:47 UTC Learn more
- Tell your friends
- Get science news via